title: Targeted therapy of multiple myeloma.
abstract: The diagnosis of multiple myeloma requires the presence of monoclonal bone marrow plasma cells, a monoclonal (M) protein in serum and/or urine and evidence of end-organ damage from the plasma cell proliferative disorder. Initial therapy for transplant-eligible patients  includes thalidomide, bortezomib or lenalidomide, all with dexamethasone. Stem cells for a possible autologous stem cell transplant (ASCT) should be collected if the patient is considered eligible for an ASCT. Initial therapy for patients ineligible for an autologous stem cell transplant includes  melphalan and prednisone as well as thalidomide, bortezomib or lenalidomide. More than 100 agents are in phase I, II or III clinical trials. The most promising are carfilzomib and pomalidomide.
authors.affiliation: Mayo Clinic, Division of Hematology, 200 First Street SW, Rochester, MN 55905, USA. kyle.robert@mayo.edu
authors.forename: Robert A
authors.initials: RA
authors.lastname: Kyle
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D003907:Dexamethasone / Q000627:therapeutic use; D006801:Humans; D000077269:Lenalidomide; D058990:Molecular Targeted Therapy / Q000379:methods; D009101:Multiple Myeloma / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D011719:Pyrazines / Q000627:therapeutic use; D055502:Secondary Prevention; D033581:Stem Cell Transplantation / Q000379:methods; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D014182:Transplantation, Autologous / Q000379:methods; D014184:Transplantation, Homologous / Q000379:methods
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D000077269:Lenalidomide